12.09
21-February-25 15:45:00
15 minutes delayed
Stocks
-0.08
-0.66%
Today's range
11.70 - 12.51
ISIN
N/A
Source
NASDAQ
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
07 Feb 2025 07:00:00 By Nasdaq GlobeNewswire